284 related articles for article (PubMed ID: 18094719)
21. RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.
Edwards H; Xie C; LaFiura KM; Dombkowski AA; Buck SA; Boerner JL; Taub JW; Matherly LH; Ge Y
Blood; 2009 Sep; 114(13):2744-52. PubMed ID: 19638627
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemia-related malignancies.
Lalonde E; Rentas S; Wertheim G; Cao K; Surrey LF; Lin F; Zhao X; Obstfeld A; Aplenc R; Luo M; Li MM
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832921
[TBL] [Abstract][Full Text] [Related]
23. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
24. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
Vyas P; Roberts I
Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
[TBL] [Abstract][Full Text] [Related]
25. Unique clinical and biological features of leukemia in Down syndrome children.
Xavier AC; Ge Y; Taub J
Expert Rev Hematol; 2010 Apr; 3(2):175-86. PubMed ID: 21083461
[TBL] [Abstract][Full Text] [Related]
26. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.
Malinge S; Izraeli S; Crispino JD
Blood; 2009 Mar; 113(12):2619-28. PubMed ID: 19139078
[TBL] [Abstract][Full Text] [Related]
27. A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21.
Stepensky P; Brooks R; Waldman E; Revel-Vilk S; Izraeli S; Resnick I; Weintraub M
Pediatr Blood Cancer; 2010 Jul; 54(7):1048-9. PubMed ID: 20108342
[TBL] [Abstract][Full Text] [Related]
28. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
[TBL] [Abstract][Full Text] [Related]
29. A novel mutation in the GATA1 gene associated with acute megakaryoblastic leukemia in a Korean Down syndrome patient.
Kim IS; Park ES; Lim JY; Ki CS; Chi HS
J Korean Med Sci; 2008 Dec; 23(6):1105-8. PubMed ID: 19119459
[TBL] [Abstract][Full Text] [Related]
30. The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis.
Alejo-Valle O; Weigert K; Bhayadia R; Ng M; Issa H; Beyer C; Emmrich S; Schuschel K; Ihling C; Sinz A; Zimmermann M; Wickenhauser C; Flasinski M; Regenyi E; Labuhn M; Reinhardt D; Yaspo ML; Heckl D; Klusmann JH
Blood; 2022 Feb; 139(5):651-665. PubMed ID: 34570885
[TBL] [Abstract][Full Text] [Related]
31. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
Satgé D
Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
[TBL] [Abstract][Full Text] [Related]
32. Myeloid leukemia in Down syndrome.
Khan I; Malinge S; Crispino J
Crit Rev Oncog; 2011; 16(1-2):25-36. PubMed ID: 22150305
[TBL] [Abstract][Full Text] [Related]
33. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis.
Klusmann JH; Godinho FJ; Heitmann K; Maroz A; Koch ML; Reinhardt D; Orkin SH; Li Z
Genes Dev; 2010 Aug; 24(15):1659-72. PubMed ID: 20679399
[TBL] [Abstract][Full Text] [Related]
34. Acute megakaryoblastic leukemia in Down syndrome.
Hitzler JK
Pediatr Blood Cancer; 2007 Dec; 49(7 Suppl):1066-9. PubMed ID: 17943965
[TBL] [Abstract][Full Text] [Related]
35. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
36. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
[TBL] [Abstract][Full Text] [Related]
37. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
38. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.
Gurbuxani S; Vyas P; Crispino JD
Blood; 2004 Jan; 103(2):399-406. PubMed ID: 14512321
[TBL] [Abstract][Full Text] [Related]
39. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
[TBL] [Abstract][Full Text] [Related]
40. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]